| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |
From the Cornell University Medical College at Burke Medical
Research Institute,*
White Plains; Cornell University
Medical College,
New York City; and the
N. S. Kline Institute,
New York
University, Orangeburg, New York
| Abstract |
|---|
|
|
|---|
| Introduction |
|---|
|
|
|---|
-ketoglutarate dehydrogenase, a thiamine-dependent, key enzyme of
the Krebs cycle, occur in many of these diseases, such as Alzheimer's
disease,14-16
Parkinson's disease,17
Wernicke-Korsakoff syndrome,13
and Friedreich's and type 1
hereditary spinocerebellar ataxias.18
Nevertheless, the
role of thiamine-dependent enzyme deficits in neurodegeneration is
still unclear. Whether these deficits are the initiating event, part of
a critical cascade, or merely a secondary phenomenon remains to be
elucidated. Experimental thiamine deficiency (TD) provides a test of
how chronic low-grade interruption of these enzymes contributes to the
brain pathology.
TD models the molecular and cellular mechanisms by which a chronic,
generalized impairment of oxidative metabolism leads to selective
neuronal loss. In rodents, TD causes a generalized reduction in the
-ketoglutarate dehydrogenase activity. Breakdown of the blood-brain
barrier (BBB) is the earliest region-specific pathological change
during TD.19,20
This is followed by cell loss and
accumulation of ß protein precursor (ßPP) immunoreactivity in
perikarya and abnormal neurites that occur either around the lesions in
rats21
or in neuritic clusters within vulnerable regions in
mice.22
The mechanisms responsible for the region-selective BBB breakdown, cell loss, and abnormal ßPP expression in TD are unknown. One possibility is that factors released from endothelial cells and microglia such as nitric oxide (NO) or free radical generators induce the damage. Recently, increased cerebral free radical production has been reported in TD.23 Although NO possesses important physiological roles in the nervous system, it is also a potential mediator of neurotoxicity in a variety of disease states. Previous studies from other models of disease suggest that excessive NO production may be linked to or even cause abnormalities in BBB permeability.24-26 Microglia are prominently involved in the pathogenesis of neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease.27 In vitro experiments demonstrate that activated microglia mediate neuronal cell injury via NO.28 The current studies tested whether NO and microglia participate in a cascade of initial events that culminate in selective cell loss during TD.
| Materials and Methods |
|---|
|
|
|---|
Adult male C57BL/6 mice (20 to 30 g; Charles River Breeding Laboratories, Wilmington, MA) or Fischer 344 Brown Norway F1 hybrid rats (250 to 300 g; Harlan Sprague Dawley, Indianapolis, IN) were housed individually in suspended wire mesh cages. As in our previous reports,19,21,22 TD was induced by ad libitum feeding of a thiamine-deficient diet (ICN Nutrition Biomedicals, Cleveland, OH) and daily intraperitoneal injection of the thiamine antagonist pyrithiamine hydrobromide (5 µg in 0.1 ml of saline/10 g body weight; Sigma Chemical Co., St. Louis, MO). Control animals received a thiamine-supplemented diet ad libitum and intraperitoneal saline injections daily (0.1 ml/10 g body weight). All animal procedures were approved by the Institutional Animal Care and Use Committee of Cornell University Medical College.
Tissue Preparation
At different stages of TD, mice (days 9, 10, and 11) and rats (days 9, 10, 11, 12, and 13) were euthanized with a lethal dose of sodium pentobarbital (6 mg/100 g intraperitoneally; Fort Dodge Laboratories, Fort Dodge, IA) and perfused transcardially with 0.9% NaCl containing heparin (10 units/ml) followed by 4% paraformaldehyde in 0.1 mol/L sodium phosphate buffer (PB; pH 7.4). Brains were removed and 35-µm free-floating sections were cut. Sections were stored in 0.1 mol/L sodium phosphate-buffered saline (PBS; pH 7.4). The current studies focused mainly on the thalamus, dorsal lateral geniculate nucleus, and inferior colliculus, three of the major brain regions consistently damaged during TD.
Immunohistochemical Detection of BBB Disturbances
Breakdown of the BBB was assessed by employing a one-step immunohistochemical detection of immunoglobulin G (IgG).29 Sections were incubated for 1 hour in horseradish peroxidase-conjugated rabbit anti-rat or anti-mouse IgG (1:500 in PBS; Sigma). Visualization of the peroxidase activity was performed by incubating the sections for 5 to 10 minutes in a substrate solution containing 0.05% 3,3'-diaminobenzidine tetrahydrochloride dihydrate (DAB) and 0.003% H2O2 in PB.
Nicotinamide Adenine Dinucleotide Phosphate Diaphorase (NADPH-d) Histochemistry
NADPH-d activity is a reasonable but not an absolute correlate of NO synthase (NOS) activity.30,31 In paraformaldehyde-fixed tissues, virtually all NADPH-dependent oxidative enzymes except NOS are inactivated.32 To detect NADPH-d activity histochemically, sections were incubated at 37°C for 1 hour in a freshly prepared solution containing 1 mg/ml ß-NADPH, 0.2 mg/ml nitroblue tetrazolium, and 0.3% Triton X-100 (all purchased from Sigma) dissolved in PB. The reaction was terminated by three washes with PB.
Immunocytochemistry
Sections were stained using modified avidin-biotin-peroxidase
immunocytochemistry.33
Endogenous peroxidase was blocked by
incubating the sections in 0.3% H2O2 in PBS
for 30 minutes. This was followed by sequential incubation in 1) PBS
containing 1% bovine serum albumin and 0.2% Triton X-100 for 30
minutes, 2) one of the primary antisera (Table 1)
diluted in PBS/0.5% bovine serum
albumin for 18 hours, 3) biotinylated anti-rabbit IgG, 1:200 in
PBS/0.5% bovine serum albumin for 1 hour, and 4)
avidin-biotin-peroxidase complex, 1:50 in PBS for 1 hour. Biotinylated
secondary antibodies and the avidin-biotin-peroxidase complex were both
purchased from Vector Laboratories (Burlingame, CA). The immunoreaction
was developed in a substrate solution containing 0.05% DAB and 0.003%
H2O2 in PB. Sections were rinsed in PB, mounted
on glass slides, dehydrated in increasing concentrations of ethanol,
cleared in xylene, and coverslipped. Specificity controls were carried
out by replacing the primary antibody with PBS/0.5% bovine serum
albumin or, in the case of nitrotyrosine, by preadsorption with 10
mmol/L 3-nitrotyrosine (Sigma).
|
Free-floating sections adjacent to those used for ferritin immunocytochemistry were stained using a lectin histochemical technique.34 Sections were treated with 0.1% Triton X-100 in PBS for 30 minutes, rinsed three times in PBS, and incubated in peroxidase-labeled Bandeiraea simplicifolia BS-I isolectin B4 (20 µg/ml in PBS/0.1% Triton X-100; Sigma) overnight at 4°C. Sections were rinsed three times in PBS, and the lectin binding sites were localized with 0.05% DAB and 0.003% H2O2.
Iron Histochemistry
Free-floating sections were mounted on gelatin-coated slides and air dried. Sections were rinsed three times in deionized water for 30 minutes and stained for iron.35,36 Sections were incubated in a solution containing 1% HCl and 1% potassium ferrocyanide at room temperature for 30 minutes and rinsed three times in deionized water for 30 minutes. The reaction was intensified by incubation in 0.5% DAB in PB for 20 minutes, followed by 0.5% DAB in PB containing 0.005% H2O2 for 15 minutes. Three rinses with deionized water for 30 minutes stopped the reaction.
| Results |
|---|
|
|
|---|
TD produced behavioral and neuropathological changes consistent with those observed in our previous studies.19,21,22 Animals exhibited motor deficits and began to lose weight after 5 to 6 days (mice) or 8 to 9 days (rats) of thiamine deprivation. Weight loss was followed by ataxia and loss of righting reflex.
Similar neuropathological changes occurred in both mice and rats,
although in the latter, the time course is longer and inducible NOS
immunoreactivity was not detected. The observations described below
apply to both species. Macroscopic examination of late-stage
thiamine-deficient mouse (day 11) or rat (day 13) brains revealed
pinpoint hemorrhages in the thalamus, mammillary body, dorsal lateral
and medial geniculate nuclei, inferior colliculus, superior and
inferior olives, and some periventricular regions. Brain ventricles
displayed edematous enlargement. Tissue cavitation of the thalamus
occurred in severe cases. Other regions such as the cortex and
hippocampus were unaffected. Table 2
summarizes the sequence of microscopic pathological alterations during
TD in mice. No apparent abnormalities were detected on day 9 of TD. At
late stages, the vulnerable regions exhibited neuronal loss
(Figure 1)
, pale neuropil, perivascular
edema, and extravasated erythrocytes.19,21,22
|
|
In thiamine-deficient mouse brain, small focal areas of increased IgG immunoreactivity appeared in susceptible regions as early as 10 days of TD before the onset of apparent cell loss and hemorrhage. These areas of IgG accumulation became larger on day 11 when hemorrhage and neuronal death were evident. On days 12 to 13, areas of IgG extravasation were very extensive.
NADPH-d Histochemistry
Under normal conditions, NADPH-d-labeled neurons occurred in specific nuclei throughout the mouse or rat brain, consistent with previous mapping studies in rats.37,38 Intensely stained neurons were sparsely scattered in all layers of the cortex, striatum, and nucleus basalis. The thalamus, central nucleus of the inferior colliculus, and the dorsal lateral and medial geniculate nuclei were virtually devoid of NADPH-d-positive neurons, or they contained only a few weakly stained cells.
Striking changes occurred in vulnerable regions of thiamine-deficient
brains. NADPH-d reactivity increased in microvessel walls within the
thalamus, inferior colliculus (Figure 2)
,
mammillary body, and medial geniculate nucleus in TD as compared with
controls. Elevated NADPH-d staining occurred as early as 10 days,
which corresponds with the first appearance of IgG accumulation.
|
All isoforms of NOS possess NADPH-d activity.31
The
responses of the three distinct NOS types to thiamine deprivation were
evaluated using antibodies that react selectively with peptide
sequences unique to endothelial, inducible, and brain NOS. Ten days of
TD enhanced endothelial NOS immunoreactivity in microvessel walls
within the thalamus (Figure 3)
. This
alteration corresponded to increased NADPH-d reactivity in blood vessel
walls. Numerous inducible NOS-immunoreactive macrophage-like cells
occurred within the thalamus beginning at day 10 of TD in mice (Figure 3)
but not in rats. Owing to the lack of a reliable marker to
distinguish between microglia and macrophages, these cells were most
likely macrophages on the basis of their morphology. Neither the
control sections nor the nonvulnerable areas of thiamine-deficient
brains exhibited these changes in NOS expression. Because of the
restricted localization of endothelial and inducible NOS
immunoreactivities, Western blot analysis was not performed.
|
NO plays an important role in several physiological processes,
including modulation of cerebral blood flow.39,40
However,
excessive NO produces oxidative damage. The reaction of superoxide with
NO generates peroxynitrite, a potent biological oxidant that cannot be
measured directly. One way to assess peroxynitrite-associated oxidative
damage is by measuring nitrotyrosine, a specific nitration product of
peroxynitrite. Localization of nitrotyrosine in axons and axon
terminals of normal adult rats has been demonstrated
ultrastructurally.41
Thus, a rabbit polyclonal antibody was
used to monitor nitrotyrosine-containing proteins. Intense
nitrotyrosine immunoreactivity was not detected in any region of
control brains. In 10- and 11-day thiamine-deficient animals,
intensely immunolabeled axons and axon terminals were observed in
the thalamus (Figure 4)
. Moderate
immunoreactivity also occurred in neuronal cytoplasm within the
thalamus. Nitrotyrosine immunoreactive structures were not detected in
the nonvulnerable areas of thiamine-deficient brains. Preadsorption of
antinitrotyrosine with 10 mmol/L 3-nitrotyrosine abolished the intense
immunoreactivity in the thalamus of TD brains (data not shown).
|
Ferritin immunoreactivity occurred in resting microglia throughout the gray matter of both control and thiamine-deficient animals. Lightly stained microglia with scanty cytoplasm and thin processes were scattered in many regions including the cerebral cortex, cerebellum, and hippocampus. Ferritin was not detectable in neurons in any region.
In thiamine-deficient brains, BBB breakdown was accompanied by the
presence of many microglia with intense ferritin immunoreactivity in
the thalamus, dorsal lateral, and medial geniculate nuclei (Figure 5)
, mammillary body, and inferior
colliculus. The immunolabeled cells possessed plump bodies with
ramified processes (Figure 5
, inset), typical of the ferritin-positive
activated microglia found in pathological brain
tissues.42,43
In adjacent sections, B.
simplicifolia BS-I isolectin B4 stained cells with the
same morphology and distribution as the ferritin-immunoreactive
microglia (data not shown). These activated microglia were absent from
unaffected TD brain regions and all areas of control brains. Light
ferritin immunoreactivity occurred in microvessels within vulnerable
regions. Intense ferritin immunolabeling was detected in microglia in
the immediate vicinity of microvessels within the vulnerable regions
(Figure 6)
. Ferritin immunostaining was
also prominent in the walls of large blood vessels and capillaries
within susceptible areas, especially the thalamus of thiamine-deficient
rats (Figure 6)
. Blood vessels were also stained in the medial
geniculate nucleus and inferior colliculus, although less frequently.
Nonvulnerable regions did not exhibit strong immunoreactivity in
microglia or microvessels.
|
|
|
| Discussion |
|---|
|
|
|---|
There are at least two possible mechanisms by which excessive vascular
NO production contributes to neurodegeneration. First, NO can alter BBB
permeability to damaging extraneuronal proteins, including IgG. For
instance, inhibition of NOS by administration of
NG-nitro-L-arginine methyl ester
hydrochloride or aminoguanidine reverses the increased BBB permeability
in focal ischemia,44
meningitis,26
and
diabetes.25
As has been suggested with amyotrophic lateral
sclerosis patients, IgG can kill cells.45
Internalization
of specific plasma proteins such as immunoglobulins, transferrin,
albumin, and
-2-macroglobulin has been reported to damage cerebellar
Purkinje cells.46
Indeed, blood proteins can inhibit
oxidative metabolism,47
which could be devastating to cells
that are already metabolically compromised by TD. A second possibility
is that vascular NO may react with superoxide, a free radical that is
also increased in TD,48
to generate peroxynitrite.
Peroxynitrite can diffuse from its vascular and microglial origin and
generate hydroxyl radicals that are deleterious to surrounding
neurons.49
The strong presence of ferritin in microvessels
and in microglia around blood vessels suggests that these glial cells
are responding to an oxidative challenge from the vessels. Earlier
studies of hypoxia in cultured oligodendrocytes provide evidence that
ferritin may serve as an antioxidant.50,51
Even though NO
and hemoglobin may serve a protective role, they failed to protect the
microvessels from oxidative damage during TD. The current report is the
first to document that the microvessels in vulnerable brain regions may
be an important site of free radical production during TD. Inducible
NOS expression in vascular cells has also been implicated in ischemic
brain injury.52
The enhancement of nitrotyrosine immunoreactivity in axons within vulnerable regions of thiamine-deficient brains provides strong evidence that oxidants derived from NO, such as peroxynitrite, are involved in TD pathology. Several mechanisms of peroxynitrite-mediated neurotoxicity have been reported. Peroxynitrite may cause neuronal energy deficiency by impairing the mitochondrial respiratory chain or the mitochondrial calcium metabolism, interfering with key enzymes of the tricarboxylic acid cycle, or DNA damage.53 Nitrotyrosine immunoreactivity is present in neurons, including those containing neurofibrillary tangles in brain tissues from cases of Alzheimer's disease but not in controls.54,55 In TD, the nitration of tyrosine does not represent a global oxidative damage, but a local, selective change, as evidenced by the absence of intense nitrotyrosine staining in spared areas. This observation is consistent with the possible participation of peroxynitrite-associated oxidative damage in selective neurodegeneration in TD. However, the specificity of nitrotyrosine as a biomarker for peroxynitrite is still subject to question.56
Ferritin induction has been reported as a measure of the brain's ability to respond to damage such as hypoxia50 and transient forebrain ischemia.36 Ferritin is an intracellular iron-sequestering protein57 found in resting microglia,42 and to a lesser extent endothelial cells58 and oligodendrocytes.11 A polyclonal antiserum against ferritin was used in the current experiments to monitor ferritin synthesis in brain cells including microglia. Ferritin is a reliable marker for microglia.42,43,59-61 In the current studies, demonstration of the specificity of ferritin antibody as a microglial marker consisted of 1) strong ferritin immunoreactivity of a known BV2 murine microglial cell line (unpublished results); 2) absence of glial fibrillary acidic protein or galactocerebroside immunoreactivity in cells similar to ferritin-positive, activated microglia within vulnerable regions in adjacent sections (data not shown) and 3) localization of the microglial marker B. simplicifolia BS-I isolectin B4 in cells with the same morphology and distribution as the ferritin-immunoreactive cells in adjacent sections (data not shown). Although ferritin is not restricted to microglia,62 immunolabeling in the current experiments was more intense in microglia than in any other cell type. Altered ferritin expression in the vulnerable regions of thiamine-deprived brains further implicates oxidative damage in the pathogenesis of TD. Ferritin synthesis can be induced by oxidative damage after hypoxia,50 by transient forebrain ischemia,36 and by hemoglobin-derived heme.51 NOS contains stoichiometric amounts of heme63 that may also contribute to induction of ferritin synthesis.
Disruption of iron homeostasis is believed to contribute to oxidative damage in many neurodegenerative diseases.5,59,64,65 Cellular iron is regulated by ferritin, which may serve as an antioxidant to protect cells from iron-catalyzed lipid peroxidation injury.50,66 Enhanced ferritin immunoreactivity is a marker of excessive iron deposition. The parallel occurrence of increased ferritin with IgG accumulation in overlapping vulnerable regions during TD suggests that excess iron originates from peripheral blood and not from degenerating neurons. Hemin iron of disrupted erythrocytes that crosses the BBB by the same mechanism as IgG is a potential source of iron. The receptors for the iron-transport protein transferrin are localized only on the apical membrane of the BBB endothelial cells.67 This highly polarized localization of transferrin receptors at the BBB supports a receptor-mediated endocytosis of iron-loaded transferrin at the BBB.67 Iron can also be released from ferritin by the free radical form of toxins or superoxide.66 Interestingly, the intrinsic iron in control animals was relatively abundant in vulnerable regions such as the thalamic nuclei, in agreement with a previous study,36 and the inferior colliculus as compared with the nonsusceptible regions. It is possible that a relatively high intrinsic iron content predisposes the vulnerable regions to iron-induced oxidative stress. Iron can initiate free radical formation, leading to lipid peroxidation and subsequent neurodegeneration.68-70 Ferritin elevation has been suggested to compensate for age-related increases in iron and to prevent accumulation of protein carbonyls, the principal product of protein oxidation.71 In Alzheimer's disease, Parkinson's disease, and multiple sclerosis, the localized elevation of iron identifies potential sites where iron could promote oxidative damage.59,65 Recently, redox-active iron has been demonstrated in Alzheimer plaques and tangles of Alzheimer's disease, suggesting that iron accumulation could be an important source of oxidative damage in Alzheimer's disease.72 These iron-containing neuritic plaques are surrounded by microglia and astrocytes that robustly immunostain for ferritin.73 Thus, increases in ferritin immunoreactivity in blood vessels and microglia in vulnerable regions indicate a response to an increased iron load and therefore represent a neuroprotective and antioxidant response to TD.
The current results show that BBB damage and NOS induction are accompanied by microglial activation. Microglia are extremely sensitive to perturbations in the brain microenvironment. Glial activation usually has a protective and supportive function, but in disease, glial cells may produce excessive cytokines that compromise neuronal function.74 Although overproduction of NO by endothelial cells, activated microglia, and macrophages may contribute to neuronal death, these cells may also be beneficial.27,75 Factors secreted by activated macrophages have been shown to reduce Alzheimer ß-amyloid protein accumulation in vascular smooth muscle cells by stimulating the nonamyloidogenic processing of ßPP.76 This finding, in combination with our current demonstration of region-specific microglial activation, may explain the failure to detect Alzheimer ß-amyloid protein in plaque-like neuritic clusters that exhibit intense ßPP immunoreactivity in affected regions from our previous mouse TD studies.22 The early increase in BBB permeability, induction of NOS, elevation of ferritin and iron, and microglial activation at the same time course suggest that these responses are part of a cascade of events that contribute to TD pathogenesis. However, the temporal resolution of the current in vivo studies could not clarify the causal relationship among these abnormalities. Understanding this relationship will help elucidate the cellular basis for selective cell death. During late stages of TD, many events occur, including N-methyl-D-aspartate-mediated excitotoxicity,77 seizures, and decreased NOS activities.78 The decline in NOS activities in late stages of TD is attributable to the neuronal loss and is not a specific reduction.
The current observations support the hypothesis that a generalized metabolic injury from TD increases NO and other free radical generators in BBB endothelial cells, resulting in breach of the BBB. The free radical-mediated alteration of the BBB permits entry of immunoglobulins and iron into the brain. The extraneuronal proteins and iron, together with the metabolic impairment itself, activate microglia to initiate an inflammatory response including excessive NO production. NO reacts with superoxide to produce peroxynitrite, which diffuses from its cell origin to form an intermediate that nitrates proteins, thereby damaging the metabolically compromised neurons. Ferritin induction in microglia represents an important neuroprotective, antioxidant defense by storing and transporting iron in forms that will not generate reactive radicals. Taken together, the current observations suggest that oxidative damage may contribute to the selective neuronal death during TD. Thus, the TD model should be useful in elucidating the relationship between oxidative deficits, BBB abnormalities, inflammatory response, ferritin and iron elevation, and selective neurodegeneration. An understanding of these interactions may provide insight into the mechanism of cell demise in human diseases in which oxidative damage, NO, and microglial ferritin and iron responses have been implicated.
| Acknowledgements |
|---|
| Footnotes |
|---|
Supported by National Institutes of Health grants AG-14600 (to GEG); AG-11508, AG-09464, AG-10491, and AG-13780 (to SEG); and AG-09014-07 (to NYC).
Accepted for publication May 18, 1998.
| References |
|---|
|
|
|---|
-ketoglutarate dehydrogenase complex activity in Alzheimer's disease. J Neurochem 1993, 61:2007-2014[Medline]
-ketoglutarate dehydrogenase complex in fibroblasts from familial Alzheimer's disease. Ann Neurol 1994, 35:312-318[Medline]
-ketoglutarate dehydrogenase complex in Parkinson's disease. Ann Neurol 1994, 35:204-210[Medline]
-ketoglutarate dehydrogenase subunits in Friedreich's ataxia and spinocerebellar ataxia type 1. Neurodegeneration 1996, 5:27-33[Medline]
This article has been cited by other articles:
![]() |
A. D. THOMSON and E. J. MARSHALL THE NATURAL HISTORY AND PATHOPHYSIOLOGY OF WERNICKE'S ENCEPHALOPATHY AND KORSAKOFF'S PSYCHOSIS Alcohol Alcohol., March 1, 2006; 41(2): 151 - 158. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. L. PALL NMDA sensitization and stimulation by peroxynitrite, nitric oxide, and organic solvents as the mechanism of chemical sensitivity in multiple chemical sensitivity FASEB J, September 1, 2002; 16(11): 1407 - 1417. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. J. Watters, J. A. Sommer, Z. A. Pfeiffer, U. Prabhu, A. N. Guerra, and P. J. Bertics A Differential Role for the Mitogen-activated Protein Kinases in Lipopolysaccharide Signaling. THE MEK/ERK PATHWAY IS NOT ESSENTIAL FOR NITRIC OXIDE AND INTERLEUKIN 1beta PRODUCTION J. Biol. Chem., March 8, 2002; 277(11): 9077 - 9087. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. L. Wang, D. L. Rainwater, J. F. VandeBerg, B. D. Mitchell, and M. C. Mahaney Genetic Contributions to Plasma Total Antioxidant Activity Arterioscler. Thromb. Vasc. Biol., July 1, 2001; 21(7): 1190 - 1195. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Ito, K. Tanaka, S. Suzuki, T. Dembo, and Y. Fukuuchi Enhanced Expression of Iba1, Ionized Calcium-Binding Adapter Molecule 1, After Transient Focal Cerebral Ischemia In Rat Brain Stroke, May 1, 2001; 32(5): 1208 - 1215. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Karten, H. Boechzelt, P. M. Abuja, M. Mittelbach, and W. Sattler Macrophage-enhanced formation of cholesteryl ester–core aldehydes during oxidation of low density lipoprotein J. Lipid Res., July 1, 1999; 40(7): 1240 - 1253. [Abstract] [Full Text] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |